ImmuCell (NASDAQ:ICCC) Releases Quarterly Earnings Results

ImmuCell (NASDAQ:ICCC) posted its earnings results on Tuesday. The biotechnology company reported $0.06 EPS for the quarter, Zacks reports. The firm had revenue of $7.75 million for the quarter. ImmuCell had a negative return on equity of 15.32% and a negative net margin of 15.99%.

ImmuCell Price Performance

Shares of ImmuCell stock traded down $0.12 on Thursday, reaching $5.36. The company’s stock had a trading volume of 357 shares, compared to its average volume of 5,925. ImmuCell has a 52-week low of $3.34 and a 52-week high of $5.82. The company has a market capitalization of $47.80 million, a P/E ratio of -10.73 and a beta of 0.54. The company has a quick ratio of 1.44, a current ratio of 3.11 and a debt-to-equity ratio of 0.36. The stock has a 50-day moving average price of $5.14 and a 200-day moving average price of $4.27.

About ImmuCell

ImmuCell Corporation, an animal health company, develops, manufactures, and sells products that enhance the health and productivity of dairy and beef cattle in the United States and internationally. The company operates through two segments, Scours and Mastitis. It offers First Defense, an orally delivered scours preventive product for calves with claims against E.